Therapy of chronic hepatitis C - virologic response monitoring;Terapija hroničnog hepatitisa C - praćenje virusološkog odgovora

Vojnosanitetski Pregled

Volumn 67, Issue 11, 2010, Pages 923-927

  Kuljić Kapulica, Nada ^a   Jovanović, Dragutin ^a   Savić, Dejana ^a   Ristanović, Elizabeta ^a   Nožić, Darko ^b   Rajić, Radmila ^b  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b Klinika za infektivne i tropske bolesti   (Serbia)

Author keywords

Genotype; Hepacivirus; Hepatitis c; Interferon alpha; Ribavirin; Rna; Virology

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; PHARMACOLOGICAL PARAMETERS; SUSTAINED VIROLOGICAL RESPONSE; VIROLOGICAL RELAPSE; VIRUS LOAD;

EID: 78549294543     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1011923K     Document Type: Article

References (19)

1. Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Rev Med Virol. 2003; 13(1):57-68.
2. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
3. Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436: 953-60.
4. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72.
5. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended teratment duration for hepatitic C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
6. Witthöft T. Review of consensus interferon in the treatment of chronic hepatitis C. Biologics 2008; 2(4): 635-43.
7. Gourlain K, Soulier A, Pellegrin B, Bouvier-Alias M, Hézode C, Darthuy F, et al. Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay. J Clin Microbiol 2005; 43(4): 1669-73.
8. Chevaliez S, Pawlotsky JM. Hepatitis C Virus Serologic and Virologic Tests and Clinical Diagnosis of HCV-Related Liver Disease. Int J Med Sci 2006; 3: 35-40.
9. Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naïve chronic hepatitis C patients. BMC Gastroenterol 2009; 9: 5.
10. Matsuura K, Tanaka Y, Hasegawa I, Ohno T, Tokuda H, Kurbanov F, et al. Abbott Real Time hepatitis C virus (HCV) and Roche Cobas Ampli Prep/Cobas Taq Man HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol 2009; 47(2): 385-9.
11. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42(4): 962-73.
12. Reesink HW, Weegink CJ. New hope for a cure for chronic hepatitis C. J Hepatol 2009; 51(4): 835-7.
13. Zeuzem S. Heterogeneous virologic response rates to interferon- based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-81.
14. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357(2): 124-34.
15. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346-55.
16. Nikolic P, Jemuovic Lj, Delic D, Korac M, Boricic I. Treatment of chronic hepatitis C with interferon alpha - our results. Acta Infectologica Yugoslavica 2000; 5: 1-9.
17. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351(5): 451-9.
18. Kumar D, Malik A, Asim M, Chakravarti A, Das RH, Kar P. Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C. World J Gastroenterol 2008; 14(5): 701-8.
19. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, et al. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 2005; 41(3): 617-25.